Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: John Powell who wrote (131)	12/2/1997 7:49:00 AM
From: Zoltan!	Read Replies (1) \| Respond to of 942

From Reuters: Edmund Debler, an analyst at Mehta and Isaly, said the developments, particularly Glaxo's cautious response, had cast doubts on troglitazone, even though relatively few patients had been shown to have suffered liver problems. ''It's definitely not good news for Warner-Lambert,'' he said, predicting the company might have to follow Glaxo's lead and withdraw the drug. ''Since one company has already suspended sales, it's hard to imagine Warner-Lambert will not pull it from the U.S. market,'' Debler said. biz.yahoo.com On the other hand, Glaxo was trading up in Europe. Regards